PNPLA3 and metabolic dysfunction-associated steatohepatitis: More recently, ION839 (AZD2693), a PNpla3-targeting ASO, was used in patients with NASH and PNPLA3 I148M in a Phase I clinical trial (NCT04483947) (Xu et al., 2022).